Chester County News and Community Website
WASHINGTON, D.C. — The Food and Drug Administration (FDA) has unveiled a new initiative aimed at reimagining homes as central hubs for health care. Announced Thursday, the Home as a …
FDA Launches Initiative to Transform Homes into Health Care Hubs Read More
WASHINGTON, D.C. — This week, in a significant step for the medical world and hope for patients, the U.S. Food and Drug Administration expanded the approval of Elevidys, a gene …
FDA Broadens Approval of Elevidys Gene Therapy for Duchenne Muscular Dystrophy Patients Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced the progression of its OCU410ST GARDian clinical trial after the Data and Safety Monitoring Board (DSMB) approved moving forward with …
Ocugen Advances Stargardt Disease Therapy with Positive Clinical Trial Progress Read More
WASHINGTON, D.C. — On Thursday, U.S. Senators Bob Casey (D-PA) and Markwayne Mullin (R-OK) introduced the Creating Hope Reauthorization Act, a bipartisan effort aimed at encouraging pharmaceutical companies to develop …
Senate Leaders Push for Reauthorization of Program to Combat Rare Pediatric Diseases Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) this week approved a new vaccine, Capvaxive, to combat invasive diseases and pneumonia caused by Streptococcus pneumoniae in adults. This approval …
FDA Approves New Pneumococcal Vaccine for Adults Read More
CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), announced key data today from two separate preclinical studies. The data provides fascinating insights into the potential effects of TRV045, a novel S1P1 …
Revolutionary Preclinical Data Unveiled by Trevena: Potential New Direction in Neuropathic Pain and Acute Seizure Management Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400, a gene therapy candidate for retinitis pigmentosa …
Ocugen Doses First Patient in Phase 3 Trial for Retinitis Pigmentosa Therapy Read More
WASHINGTON, D.C. — On Monday, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) in combination with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary …
FDA Approves Keytruda Combination for Advanced Endometrial Cancer Read More
MALVERN, PA — Actress and humanitarian Ashley Judd will speak at HMP Global’s 2024 Psych Congress in Boston. She will join a fireside chat with Christine Yu Moutier, MD, Chief …
Ashley Judd to Speak at Psych Congress 2024 on Mental Health and Suicide Prevention Read More
WASHINGTON, D.C. — On Friday, the Food and Drug Administration (FDA) approved durvalumab (Imfinzi, AstraZeneca UK Limited) for use with carboplatin plus paclitaxel followed by single-agent durvalumab. This approval targets …
FDA Approves New Treatment for Advanced Endometrial Cancer Read More